semaglutide prediabetes weight loss trial progression to diabetes Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous 2.4 mg Among Participants With in the STEP Program Semaglutide: Review and Place in

Tirzepetide : This newer medication is also a GLP-1 receptor agonist but works by targeting both GLP-1 and GIP (gastric inhibitory polypeptide) receptors, which may offer enhanced weight loss and metabolic benefits

Cold sensitivity on tirzepatide is not a recognised serious adverse effect and typically relates to weight loss rather than direct medication toxicity

Later Period Treatment Changes During Follow-Up SGLT2i Cohort Among patients still under observation at 12 months, 55.0% were receiving treatment at 1 year (Fig

Reviewing concurrent medications with a GP or pharmacist can identify potential contributors to cramping, particularly diuretics, SGLT2 inhibitors, and statins

Alternate appointment formats, including video or phone, are available to suit your lifestyle